Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Drug Profile

Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; Varlitinib tosylate

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals
  • Class Antineoplastics; Diamines; Oxazoles; Quinazolines; Small molecules; Thiazoles
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II/III Gastric cancer
  • Phase II Breast cancer; Cholangiocarcinoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Hepatocellular carcinoma

Most Recent Events

  • 10 Aug 2018 Aslan Pharmaceuticals completes enrolment in phase II portion of phase II/III trial for Gastric cancer (First-line therapy, Combination therapy, Metastatic disease, Late-stage disease)
  • 06 Jun 2018 Aslan Pharmaceuticals completes a phase I trial in Solid tumours and Biliary cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Japan (PO) (NCT03082053)
  • 21 May 2018 Aslan Pharmaceuticals withdraws a phase II trial prior to enrolment due to sponsor decision for Biliary cancer (Metastatic disease, Late-stage disease, First-line therapy, Inoperable/unresectable, Combination therapy) in Australia, China, Hong Kong, Hungary, Japan, Poland, Singapore, South Korea, Spain, Taiwan and USA (PO) (NCT03129074).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top